Cytokinetics (CYTK)
Cytokinetics Total Assets: 46.53M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CYTK Total Assets Rankings
| Overall | 8th percentile | 3996 of 4386 |
| Sector | 24th percentile | 381 of 504 in Healthcare |
| Industry | 30th percentile | 111 of 159 in Biotechnology |
CYTK Total Assets Range, Past 5 Years
| Minimum | 46.53M | Mar 2012 |
| Maximum | 172.81M | Jun 2007 |
| Average | 105.11M |
About Total Assets
The sum of all current and long-term assets held by a company. An asset is any item with economic value that is held by a company.
Learn More
You may also be interested in these CYTK related companies
CYTK News
$CYTK forms bearish "Continuation Diamond" chart pattern. http://stks.co/3aqN
about 28 days ago by RecogniaEvents
about 28 days ago by RecogniaEvents
@Jamtrades @seekingalpha when they use the term encouiraging it usually means its crap $CYTK
about 33 days ago by lieberlanz
about 33 days ago by lieberlanz
Cytokinetics (CYTK) Proposed Muscle Troponin Activator Now on FDA's Fast Track
Apr 19, 8:53AM Street Insider
Apr 19, 8:53AM Street Insider
$CYTK forms bearish "Head and Shoulders Top" chart pattern. http://stks.co/3IOW
about 48 days ago by RecogniaEvents
about 48 days ago by RecogniaEvents
$CYTK filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3BjU
about 56 days ago by MarketBrief
about 56 days ago by MarketBrief
Cytokinetics to Present at the Eleventh Annual Needham Life Sciences Conference
Mar 27, 4:13PM Marketwire
Mar 27, 4:13PM Marketwire
@ChiBullsTrader @ChillzTrading Agree! May add position for that event; already have $CYTK for the same conference.
about 68 days ago by Chilltill
about 68 days ago by Chilltill
$CYTK forms bullish "Diamond Bottom" chart pattern. http://stks.co/2kad
about 81 days ago by RecogniaEvents
about 81 days ago by RecogniaEvents
Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Feb 02, 4:13PM Street Insider
Feb 02, 4:13PM Street Insider
Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2011 Financial Results
Feb 02, 4:00PM Marketwire
Feb 02, 4:00PM Marketwire
Cytokinetics to Announce Fourth Quarter and Year End Results on February 2, 2012
Jan 26, 4:00PM Marketwire
Jan 26, 4:00PM Marketwire
Cytokinetics (CYTK) Reports Positive CK-2017357 Phase II, Part A Dat in ALS Patients
Nov 30, 7:32AM Street Insider
Nov 30, 7:32AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYTK | 0.93 | +0.02 | +2.20% | 71.03M |
| CYT | 60.59 | -0.40 | -0.66% | 2.777B |
| CYS | 13.80 | -0.06 | -0.43% | 1.541B |
| CYOU | 21.81 | +0.12 | +0.55% | 1.145B |
| CYN | 50.25 | -0.29 | -0.57% | 2.674B |
| CYMI | 53.30 | -0.08 | -0.15% | 1.643B |
| CYH | 22.66 | +0.28 | +1.25% | 2.075B |
| CYE | 7.55 | +0.05 | +0.67% | |
| CYCC | 0.5124 | -0.02 | -3.32% | 27.79M |
| CYBI | 1.761 | -0.03 | -1.62% | 30.15M |
